Imbruvica’s Second-line CLL Claim Still “Powerful And Inclusive”
This article was originally published in The Pink Sheet Daily
Executive Summary
Overall response rate cited in labeling is 13% lower in the small, single arm study supporting accelerated approval compared to previous reports, but Pharmacyclics is sure it can explain data nuances to prescribers.